Document Detail


The cost of preterm birth: the low cost versus high value of tocolysis.
MedLine Citation:
PMID:  17206959     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The consequences of preterm birth (PTB), to the individual and society at large, remain a major financial and personal burden. Babies born at the limits of viability, who survive, often have major neurological impairments, such as cerebral palsy, developmental delay and blindness. The cost of initial hospitalisation is more than $200,000 for each birth but takes no account of future costs once they leave the hospital. The major morbidities associated with extreme prematurity are respiratory distress syndrome (RDS), intraventricular haemorrhage (IVH) and necrotising enterocolitis (NEC). With advancing gestational age at birth, the financial costs and morbidity associated with these conditions decrease. The major morbidities (RDS, IVH and NEC) are rare by 34 weeks of gestation, with the exception of RDS, which complicates 7% of deliveries at this gestational age. While the vast majority of infants survive the first year of life, the infant mortality rate is markedly increased by three- to five-fold even for the mildly preterm infants, as compared with that of the term infants. Neonates born after 34 completed weeks of gestation rarely have mortality or major morbidity, but the financial costs remain significant ($7000 per case), and efforts to prevent delivery at this gestational age are probably indicated. Economic costs associated with PTB include the cost of initial hospitalisation, the cost of any chronic diseases resulting from the prematurity and social costs including loss of gainful employment by a family member taking care of the infant or child and loss of potential future earnings of the affected child. Antenatal steroids, if given to the mother at least 48 hours prior to a PTB, have shown significant reductions in RDS, IVH and NEC. Efforts to prevent, or avoid, PTB include the use of tocolytic agents which have been shown to prolong gestation for a minimum of 48 hours, or longer in some cases. The range of tocolytic agents used to delay or prevent PTB work through many different pathways, with varying degrees of success. Which tocolytic agent to use depends on many factors including underlying maternal status, gestational age of the fetus and documented efficacy of agent used.
Authors:
W M Gilbert
Related Documents :
16700389 - Morbidity and mortality of low-birth-weight infants in egypt.
10389499 - Early neonatal morbidity and mortality in a city based medical college nursery.
16368579 - A comparison of the effectiveness of single-dose vs multi-dose antenatal corticosteroid...
8164699 - Effect of surfactant on morbidity, mortality, and resource use in newborn infants weigh...
21890289 - Maternal use of selective serotonin reuptake inhibitors during pregnancy and neonatal b...
23083969 - Videolaryngoscopy versus direct laryngoscopy in simulated pediatric intubation.
9662109 - Diphenhydramine toxicity: comparisons of postmortem findings in diphenhydramine-, cocai...
15214359 - Ximelagatran for prevention and treatment of venous thromboembolism.
19482669 - S100b milk concentration in mammalian species.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  BJOG : an international journal of obstetrics and gynaecology     Volume:  113 Suppl 3     ISSN:  1470-0328     ISO Abbreviation:  BJOG     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2007-01-08     Completed Date:  2007-04-24     Revised Date:  2008-03-25    
Medline Journal Info:
Nlm Unique ID:  100935741     Medline TA:  BJOG     Country:  England    
Other Details:
Languages:  eng     Pagination:  4-9     Citation Subset:  AIM; IM    
Affiliation:
Women's Services, Sutter Health, Sacramento, CA, USA. gilberw@sutterhealth.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cost of Illness*
Female
Humans
Infant Mortality
Infant, Newborn
Intensive Care Units, Neonatal
Morbidity
Patient Readmission
Pregnancy
Premature Birth / drug therapy*,  economics*
Tocolytic Agents / therapeutic use*
Chemical
Reg. No./Substance:
0/Tocolytic Agents
Comments/Corrections
Erratum In:
BJOG. 2008 Apr;115(5):674-5

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The epidemiology of preterm labour--why have advances not equated to reduced incidence?
Next Document:  EPICure: facts and figures: why preterm labour should be treated.